The reacquisition of bota-vec represents a significant strategic move, bringing back a late-stage asset with strong clinical data and regulatory incentives. The company's immediate plan to file for approval suggests confidence in the data package and regulatory pathway. Traders should monitor the progress of regulatory filings in the U.S. and EU, as well as any updates on the $200 million Hologen joint venture, which could provide additional non-dilutive funding for this and other programs.
Price Chart
Executive Summary
MeiraGTx reacquired the gene therapy candidate botaretigene sparoparvovec (bota-vec) for X-linked retinitis pigmentosa from Johnson & Johnson for $25 million upfront, with potential future milestone payments and royalties. The deal follows the company's prior divestiture of the asset and includes strong Phase 3 data showing significant improvements in retinal function and vision, with the company planning immediate regulatory filings for approval.
Key Financial Metrics
Key Facts
- MeiraGTx reacquired bota-vec from J&J for $25 million upfront cash payment
- Potential $50 million milestone payment upon U.S. regulatory approval and $250 million in U.S. sales
- High double-digit royalties on global net sales starting mid-2029
- Phase 3 LUMEOS study showed statistically significant improvements in retinal sensitivity, low luminance vision, and patient-reported outcomes
- 40% of treated patients showed improvement in two endpoints vs. 0% in control group
- FDA Fast Track and Orphan Drug designations; EU PRIME and ATMP designations granted
- MeiraGTx is commercial manufacturer with completed PPQ and regulatory licenses
Financial Impact
Immediate $25 million cash outflow; potential $50 million milestone payment; high double-digit royalty payments on future sales
Risk Factors
- Regulatory approval not guaranteed despite positive data
- Competition from other gene therapies in development
- Manufacturing scalability and commercialization challenges
- Dilutive financing risk if additional capital is needed
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-044028 |
| Document: mgtx-20260415xex99d2.htm | 0001104659-26-044028 |
| Document: mgtx-20260415x8k.htm | 0001104659-26-044028 |
| Document: mgtx-20260415xex10d2.htm | 0001104659-26-044028 |
| Document: mgtx-20260415xex99d1.htm | 0001104659-26-044028 |
| Document: 0001104659-26-044028-index-headers.html | 0001104659-26-044028 |
| Document: 0001104659-26-044028-index.html | 0001104659-26-044028 |
| Document: 0001104659-26-044028.txt | 0001104659-26-044028 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 20d ago | 144 | $10.82 | awaiting T+60 | — | $9.18 (−15.16%) |
Sep 24, 2026 4w ago | 3 | $10.91 | awaiting T+60 | — | $9.18 (−15.86%) |
Sep 23, 2026 4w ago | 8-K | $11.75 | awaiting T+60 | — | $9.18 (−21.87%) |
Aug 18, 2026 9w ago | 144 | $14.97 | awaiting T+60 | — | $9.18 (−38.68%) |
Aug 13, 2026 10w ago | 8-K | $12.67 | awaiting T+60 | — | $9.18 (−27.55%) |
Aug 13, 2026 10w ago | Press Release | $12.67 | awaiting T+60 | — | $9.18 (−27.55%) |
Jul 7, 2026 15w ago | 8-K | $14.66 $11.00 | ▼ −24.97% | ▼ −26.96% | $9.18 (−37.38%) |
May 19, 2026 22w ago | 144 | $9.58 $13.52 | ▲ +41.13% | ▲ +36.12% | $9.18 (−4.18%) |
May 14, 2026 23w ago | 8-K | $9.95 $13.02 | ▲ +30.85% | ▲ +27.27% | $9.18 (−7.74%) |
May 14, 2026 23w ago | Press Release | $9.95 $13.02 | ▲ +30.85% | ▲ +27.27% | $9.18 (−7.74%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers